<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>ESCMID on Russell E. Lewis</title>
    <link>https://russlewisid.com/categories/escmid/</link>
    <description>Recent content in ESCMID on Russell E. Lewis</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Thu, 07 Apr 2022 00:00:00 +0000</lastBuildDate><atom:link href="https://russlewisid.com/categories/escmid/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Developing time to blood culture positivity (Tpos) as a pharmacodynamic biomarker</title>
      <link>https://russlewisid.com/project/giraffes/</link>
      <pubDate>Thu, 07 Apr 2022 00:00:00 +0000</pubDate>
      
      <guid>https://russlewisid.com/project/giraffes/</guid>
      <description>Project website: www.acuteblood.com
PI: Irene Zaghi, M.D. Recipient of the 2022 ESCMID Young Investigator Award ESCMID research award link The effectiveness of antibiotic therapy in critically-ill patients with sepsis is often compromised by highly variable pharmacokinetics that can lead to subtherapeutic exposures and treatment failures, especially in the management of infections caused by multidrug resistant Gram-negative bacteria. Pharmacometric model-informed dosing and therapeutic drug monitoring (TDM) have been advanced as strategies for individualising antibiotic dosing in critically-ill patients, but the availability of these tools and expertise for implementation (especially for newer antibiotics) is often not available.</description>
    </item>
    
  </channel>
</rss>
